


Butabindide oxalate

Cat. No.:	HY-107759
CAS No.:	185213-03-0
Molecular Formula:	C ₁₉ H ₂₇ N ₃ O ₆
Molecular Weight:	393.43
Target:	Others
Pathway:	Others
Storage:	<div> <div>Powder</div> <div> -20°C 3 years 4°C 2 years </div> </div> <div> <div>In solvent</div> <div> -80°C 6 months -20°C 1 month </div> </div>



SOLVENT & SOLUBILITY

In Vitro

H₂O : 39 mg/mL (99.13 mM; Need ultrasonic and warming)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.5417 mL	12.7087 mL	25.4175 mL
	5 mM		0.5083 mL	2.5417 mL	5.0835 mL
	10 mM		0.2542 mL	1.2709 mL	2.5417 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Butabindide (UCL-1397) oxalate is a potent, selective tripeptidyl peptidase II (TPP II) inhibitor with K_i values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide oxalate inhibits TPP II to protect CCK-8 against inactivation^{[1][2]}.

IC₅₀ & Target

IC₅₀: 7 nM (TPP II) and 10 μM (TPP I)^[1]

In Vitro

Butabindide (UCL-1397; 0-24 nM; membranes of rat cerebral cortex) oxalate inhibits TPP II activity of cerebral membranes^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Butabindide (UCL-1397; 10 mg/kg; i.v.; for 20 min) oxalate inhibits the breakdown of CCK-8 in the gastrointestinal tract and increases satiety in mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice (25-30 g) ^[2]
---------------	-------------------------------

Dosage:	10 mg/kg
Administration:	Intravenous injection; for 20 minutes
Result:	Reduces food intake and elicits other behavioral concomitants of satiation.

REFERENCES

- [1]. Ganellin CR, et, al. Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors. J Med Chem. 2005 Nov 17;48(23):7333-42.
- [2]. Rose C, et, al. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature. 1996 Apr 4;380(6573):403-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA